Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ALNY 
Alnylam Pharmaceuticals Inc (ALNY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ALNY (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -2.95% | Avg. Invested days 28 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 33.10B USD | Price to earnings Ratio - | 1Y Target Price 314.17 |
Price to earnings Ratio - | 1Y Target Price 314.17 | ||
Volume (30-day avg) 893709 | Beta 0.39 | 52 Weeks Range 141.98 - 304.39 | Updated Date 04/1/2025 |
52 Weeks Range 141.98 - 304.39 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.19 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -12.37% | Operating Margin (TTM) -17.73% |
Management Effectiveness
Return on Assets (TTM) -2.74% | Return on Equity (TTM) -1500.66% |
Valuation
Trailing PE - | Forward PE 909.09 | Enterprise Value 31703681241 | Price to Sales(TTM) 14.72 |
Enterprise Value 31703681241 | Price to Sales(TTM) 14.72 | ||
Enterprise Value to Revenue 14.1 | Enterprise Value to EBITDA 204.85 | Shares Outstanding 129427000 | Shares Floating 124460110 |
Shares Outstanding 129427000 | Shares Floating 124460110 | ||
Percent Insiders 3.87 | Percent Institutions 96.39 |
Analyst Ratings
Rating 3.94 | Target Price 298.97 | Buy 11 | Strong Buy 11 |
Buy 11 | Strong Buy 11 | ||
Hold 8 | Sell 1 | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
Alnylam Pharmaceuticals Inc
Company Overview
History and Background
Alnylam Pharmaceuticals, founded in 2002, pioneered RNA interference (RNAi) therapeutics, a novel approach to treating diseases by silencing specific genes. They have achieved significant milestones in developing and commercializing RNAi drugs.
Core Business Areas
- RNAi Therapeutics: Focuses on discovering, developing, and commercializing RNAi-based therapeutics for genetically defined diseases.
Leadership and Structure
Alnylam is led by CEO Yvonne Greenstreet. The company has a traditional biotech organizational structure with departments for research, development, commercial, and administrative functions.
Top Products and Market Share
Key Offerings
- ONPATTRO (patisiran): A transthyretin (TTR) amyloidosis-directed RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy. Revenue for 2023 was $729.5 million. Main competitors are Pfizer (VYNDAMAX/VYNDAQEL) and Ionis Pharmaceuticals (TEGSEDI). Market share for TTR amyloidosis is highly competitive, with Alnylam and Pfizer being major players.
- GIVLAARI (givosiran): An RNAi therapeutic for the treatment of acute hepatic porphyria (AHP). Revenue for 2023 was $186.7 million. There are limited competing therapies but examples include Dojindo (ALASENSETM) and Recordati Rare Diseases. ALASENSETM is approved for use only in Japan.
- OXLUMO (lumasiran): An RNAi therapeutic for the treatment of primary hyperoxaluria type 1 (PH1). Revenue for 2023 was $140.2 million. There are limited competing therapies but examples include Dicerna Pharmaceuticals (nedosiran) which was acquired by Novo Nordisk.
- AMVUTTRA (vutrisiran): An RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy. Revenue for 2023 was $268.8 million. Main competitors are Pfizer (VYNDAMAX/VYNDAQEL) and Ionis Pharmaceuticals (TEGSEDI).
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high R&D costs, and regulatory scrutiny. Novel therapies and personalized medicine are key trends.
Positioning
Alnylam is a leader in RNAi therapeutics, giving them a competitive edge in addressing genetically defined diseases.
Total Addressable Market (TAM)
The total addressable market for rare diseases is estimated to be in the billions of dollars. Alnylam is well-positioned within this TAM, especially with their RNAi-based platform.
Upturn SWOT Analysis
Strengths
- Pioneering RNAi technology
- Established pipeline of approved therapies
- Strong intellectual property position
- Experienced management team
Weaknesses
- High R&D costs
- Dependence on a novel technology platform
- Limited market penetration in some therapeutic areas
- Reliance on strategic partnerships for certain programs
Opportunities
- Expansion of RNAi technology to new therapeutic areas
- Strategic acquisitions and collaborations
- Development of personalized medicine approaches
- Global market expansion
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and approval delays
- Patent challenges
- Clinical trial failures
Competitors and Market Share
Key Competitors
- PFE
- IONS
- NVO
Competitive Landscape
Alnylam has a competitive advantage in RNAi technology but faces strong competition from larger pharmaceutical companies with established market presence and resources.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Alnylam has experienced significant growth in recent years due to the commercial success of its RNAi therapeutics.
Future Projections: Analysts project continued growth for Alnylam as they expand their pipeline and gain market share.
Recent Initiatives: Recent initiatives include expansion of its pipeline, collaborations with other pharmaceutical companies, and investment in manufacturing capabilities.
Summary
Alnylam Pharmaceuticals is a pioneer in RNAi therapeutics with a growing portfolio of approved products. Its strengths lie in its innovative technology and expanding pipeline. However, high R&D costs and competition pose challenges. Alnylam needs to continue to execute its clinical programs and expand its commercial reach to solidify its position.
Similar Companies
IONS
Ionis Pharmaceuticals Inc
IONS
Ionis Pharmaceuticals Inc
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
MRNA
Moderna Inc
MRNA
Moderna Inc
PFE
Pfizer Inc
PFE
Pfizer Inc
Sources and Disclaimers
Data Sources:
- Company Reports
- Analyst Reports
- Industry Databases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alnylam Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2004-05-28 | CEO & Director Dr. Yvonne L. Greenstreet M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2230 | Website https://www.alnylam.com |
Full time employees 2230 | Website https://www.alnylam.com | ||
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.